“Existing diagnosis and treatment care models for AFib have been shown to be complex, time consuming and disconnected with disparate guidelines and poor guideline adherence,” said Eigil Samset, PhD, general manager, Cardiology Solutions, GE HealthCare. “With CardioVisio for AFib, we’re providing cardiologists with a powerful tool to tell the story of the heart, including previous diagnoses, prescribed medications, interventions, and comorbidities.”
CardioVisio for AFib assists the clinician in visualizing longitudinal data relevant for disease progression from multiple data sources, saving time and aiding clinical decision making by offering guideline-directed therapy recommendations. Each automated step includes explainability and traceability, allowing the healthcare provider to audit and edit the process and output with the goal of better meeting the unique needs of each AFib patient.
CardioVisio for Atrial Fibrillation is now commercially available in the U.S. The company plans to expand availability in other regions in the coming months incorporating additional regional guidelines.
For more information, visit: https://bit.ly/3tc8MCl
Digital issue: Please click here for more information